↓ Skip to main content

Isoniazid for preventing tuberculosis in non-HIV infected persons

Overview of attention for article published in Cochrane database of systematic reviews, January 1999
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
331 Dimensions

Readers on

mendeley
226 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Isoniazid for preventing tuberculosis in non-HIV infected persons
Published in
Cochrane database of systematic reviews, January 1999
DOI 10.1002/14651858.cd001363
Pubmed ID
Authors

Marek Smieja, Catherine Marchetti, Deborah Cook, Fiona M Smaill

Abstract

Although isoniazid (INH) is commonly used for treating tuberculosis (TB), it is also effective as preventive therapy. The objective of this review was to estimate the effect of 6 and 12 month courses of INH for preventing TB in HIV-negative people at increased risk of developing active TB. We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, Medline, Embase and reference lists of articles. We hand-searched Science Citation Index and Index Medicus. Randomised trials of INH preventive therapy for 6 months or more compared with placebo. Follow-up for a minimum of 2 years. Trials enrolling patients with current or previously treated active TB, or with known HIV infection, were excluded. Criteria were applied by two reviewers independently. Trial quality was assessed by two reviewers independently, and data extracted by one reviewer using a standardized extraction form. Eleven trials involving 73,375 patients were included. Trials were generally of high quality. Treatment with INH resulted in a relative risk (RR) of developing active TB of 0.40, (95% confidence interval ¿CI¿ 0.31 to 0.52), over two years or longer. There was no significant difference between 6 and 12 month courses (RR of 0.44, 95% CI 0.27 to 0.73 for six months, and 0.38, 95% CI 0.28 to 0.50 for 12 months). Preventive therapy reduced deaths from TB, but this effect was not seen for all cause mortality. INH was associated with hepatotoxicity in 0.36% of people on 6 months treatment and in 0.52% of people treated for 12 months. Isoniazid is effective for the prevention of active TB in diverse at-risk patients, and six and 12 month regimens have a similar effect.

Mendeley readers

The data shown below were compiled from readership statistics for 226 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 1%
Kenya 2 <1%
Brazil 1 <1%
Netherlands 1 <1%
Singapore 1 <1%
Belgium 1 <1%
Japan 1 <1%
Colombia 1 <1%
Unknown 215 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 46 20%
Student > Master 41 18%
Student > Ph. D. Student 22 10%
Student > Bachelor 19 8%
Student > Postgraduate 14 6%
Other 53 23%
Unknown 31 14%
Readers by discipline Count As %
Medicine and Dentistry 115 51%
Nursing and Health Professions 16 7%
Agricultural and Biological Sciences 10 4%
Pharmacology, Toxicology and Pharmaceutical Science 9 4%
Immunology and Microbiology 6 3%
Other 25 11%
Unknown 45 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2020.
All research outputs
#3,285,138
of 16,522,288 outputs
Outputs from Cochrane database of systematic reviews
#6,094
of 11,525 outputs
Outputs of similar age
#40,822
of 206,361 outputs
Outputs of similar age from Cochrane database of systematic reviews
#137
of 222 outputs
Altmetric has tracked 16,522,288 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.4. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,361 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 222 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.